Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan

Ann N Y Acad Sci. 2000:922:349-51. doi: 10.1111/j.1749-6632.2000.tb07062.x.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II

MeSH terms

  • Antineoplastic Agents, Phytogenic / adverse effects
  • Antineoplastic Agents, Phytogenic / pharmacokinetics
  • Antineoplastic Agents, Phytogenic / therapeutic use*
  • Bridged-Ring Compounds / therapeutic use
  • Camptothecin / adverse effects
  • Camptothecin / analogs & derivatives
  • Camptothecin / therapeutic use*
  • Drug Administration Schedule
  • Drug Resistance, Multiple
  • Fallopian Tube Neoplasms / drug therapy*
  • Female
  • Humans
  • Infusions, Intravenous
  • Ovarian Neoplasms / drug therapy*
  • Peritoneal Neoplasms / drug therapy*
  • Platinum Compounds / therapeutic use
  • Taxoids*
  • Topotecan / therapeutic use

Substances

  • Antineoplastic Agents, Phytogenic
  • Bridged-Ring Compounds
  • Platinum Compounds
  • Taxoids
  • taxane
  • Topotecan
  • exatecan
  • Camptothecin